On April 8, 2019, Nice & Green SA (N&G) and Kuros Biosciences AG (Kuros) entered into an investment agreement regarding N&G's investment of up to CHF 5 m in Kuros. The investment is made on the basis of an equity-lined debt instrument issued by Kuros consisting of convertible notes issued in twelve equal tranches representing 100,000 shares to be drawn over twelve months against issuance of convertible notes. The convertible notes are mandatory convertible into equity at the discretion of N&G within a period of 12 months after their issuance, with a conversion rate of 95% of the lowest volume-weighted average price during the six trading days preceding the conversion date.
Based in Nyon, Switzerland, N&G is a private company which specializes in financing solutions tailored to the requirements of listed growth companies in the biotech and cleantech industries.
Homburger acts as legal advisor to N&G in connection with the investment agreement. The Homburger team is led by partner Frank Gerhard and includes associate Nicola Togni (both Corporate | M&A).